Ignite Creation Date:
2024-05-06 @ 7:29 AM
Last Modification Date:
2024-10-26 @ 11:49 AM
Study NCT ID:
NCT02542293
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2015-08-26
Brief Title:
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer NSCLC NEPTUNE
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Organization Data
Organization:
AstraZeneca
Class:
INDUSTRY
Study ID:
D419AC00003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AstraZeneca
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None